Icelanders' DNA Helps Map Disease

Article

REYKJAVIK, Iceland-Pharmaceutical company Hoffman-La Roche will try to develop a schizophrenia drug based on information from the Icelandic gene pool.

A research project done by deCODE genetics in Iceland has been using the entire Icelandic population as a study subject. Kari Stefansson, deCODE CEO, said the majority of the country's 270,000 people have been included in the DNA database.

Roche agreed to pay the company $200 million for information gathered from the country's DNA. Since the deal was signed in February 1998, deCode has found genes related to eight different diseases.

The schizophrenia gene encodes a protein that appears to be involved with the disease itself. Another protein that interacts with the one made by the gene may also provide a target for a drug.

Schizophrenia affects 1% of the global population and usually appears during adolescence or young adulthood. Drugs can currently control hallucinations, delusions, and emotional disturbances caused by the disease.

Information from www.arizonarepublic.com

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
"Top 5" in a blue ribbon  (Adobe Stock 235182652 by Evgeny)
Bug of the Month
David J. Weber, MD, MPH, president of the Society for Healthcare Epidemiology of America
© 2025 MJH Life Sciences

All rights reserved.